Montserrat Blanco-Codesido

Cilastatin protects against cisplatin-induced nephrotoxicity without compromising its anticancer efficiency in rats

Blanca Humanes, Alberto Lázaro, Sonia Camaño et al. · Kidney International · 2012 · 100 citations · Full text

Chemoprevention Strategy, Cisplatin-induced Nephrotoxicity, Medicine +5

1157O A multi-cohort phase II study of durvalumab plus tremelimumab for the treatment of patients (pts) with advanced neuroendocrine neoplasms (NENs) of gastroenteropancreatic or lung origin: The DUNE trial (GETNE 1601)

Jaume Capdevila, Àlex Teulé, Carlos López et al. · Annals of Oncology · 2020 · 47 citations · Full text

Lung Origin, Endocrine Oncology, Getne 1601 +8

A Phase I, Dose-Escalation Study of the Multitargeted Receptor Tyrosine Kinase Inhibitor, Golvatinib, in Patients with Advanced Solid Tumors

L. Rhoda Molife, Emma Dean, Montserrat Blanco-Codesido et al. · Clinical Cancer Research · 2014 · 29 citations

A phase I safety and pharmacokinetic (PK) study of navitoclax (N) in combination with docetaxel (D) in patients (pts) with solid tumors.

M. Puglisi, Leni van Doorn, Montserrat Blanco-Codesido et al. · Journal of Clinical Oncology · 2011 · 23 citations

Chemoprevention Strategy, Solid Tumors, Pharmacotherapy +16

First results from a phase I trial of AZD8055, a dual mTORC1 and mTORC2 inhibitor.

Udai Banerji, Carol Aghajanian, Éric Raymond et al. · Journal of Clinical Oncology · 2011 · 23 citations

Non-tolerated Dose, Pharmacotherapy, Tumor Biology +22